Health care costs: How do we decide value? When do we decide? How do we particularize the decisions?

Oncologist

Volumn 17, Issue 2, 2012, Pages 157-159

  Theriault, Richard L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

BREAST CANCER; CANCER CENTER; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HUMAN; MEDICAL DECISION MAKING; METASTASIS; NOTE; ONCOGENE NEU; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; RECEPTOR, ERBB-2;

EID: 84930482069     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0371     Document Type: Note

References (28)

1. Sullivan R, Peppercorn J, Sikora K et al. Delivering affordable cancer care in high-income countries. Lancet Oncol 2011;12:933-980.
2. Macready N. The climbing costs of cancer care. J Natl Cancer Inst 2011;103:1433-1435.
3. Fojo T, Grady C. How much is life worth: Cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst 2009;101: 1044-1048.
4. Sox HC, Greenfield S. Comparative effectiveness research: A report from the Institute of Medicine. Ann Intern Med 2009;151:203-205.
5. Duff JM, Leather H, Walden EO et al. Adequacy of published oncology randomized controlled trials to provide therapeutic details needed for clinical application. J Natl Cancer Inst 2010; 102:702-705.
6. Claxton K, Sculpher M, Drummond M. A rational framework for decision making by the National Institute For Clinical Excellence (NICE). The Lancet 2002;360:711-715.
7. Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. BMJ 2004;329:224-227.
8. Raftery J. NICE and the challenge of cancer drugs. BMJ 2009;338:b67.
9. Russell LB, Gold MR, Siegel JE et al. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996;276:1172-1177.
10. Weinstein MC, Siegel JE, Gold MR et al. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996;276:1253-1258.
11. Hedden L, O'Reilly S, Lohrisch C et al. Assessing the real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu positive breast cancer. The Oncologist 2012;7:164-171.
12. de Lima Lopes G Jr. Societal costs and benefits of treatment with trastuzumab in patients with early HER2neu-overexpressing breast cancer in Singapore. BMC Cancer 2011;11:178.
13. Purmonen TT, Pänkäläinen E, Turunen JH et al. Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: Cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial. Acta Oncol 2011;50:344-352.
14. Danese MD, Lalla D, Brammer M et al. Estimating recurrences prevented from using trastuzumab in HER-2/neu-positive adjuvant breast cancer in the United States. Cancer 2010;116: 5575-5583.
15. Macedo A, Monteiro I, Andrade S et al. [Costeffectiveness of trastuzumab in the treatment of early stages breast cancer patients, in Portugal]. Acta Med Port 2010;23:475-482. In Portuguese.
16. Chen W, Jiang Z, Shao Z et al. An economic evaluation of adjuvant trastuzumab therapy in HER2-positive early breast cancer. Value Health 2009;12(suppl 3):S82-S84.
17. Ward S, Pilgrim H, Hind D. Trastuzumab for the treatment of primary breast cancer in HER2-positive women: A single technology appraisal. Health Technol Assess 2009;13(suppl 1):1-6.
18. Skedgel C, Rayson D, Younis T. The costutility of sequential adjuvant trastuzumab in women with Her2/Neu-positive breast cancer: An analysis based on updated results from the HERA Trial. Value Health 2009;12:641-648.
19. Van Vlaenderen I, Canon JL, Cocquyt V et al. Trastuzumab treatment of early stage breast cancer is cost-effective from the perspective of the Belgian health care authorities. Acta Clin Belg 2009;64: 100-112.
20. Chan AL, Leung HW, Lu CL et al. Cost-effectiveness of trastuzumab as adjuvant therapy for early breast cancer:Asystematic review. Ann Pharmacother 2009;43:296-303.
21. McKeage K, Lyseng-Williamson KA. Trastuzumab: A pharmacoeconomic review of its use in early breast cancer. Pharmacoeconomics 2008;26: 699-719.
22. Neyt M, Huybrechts M, Hulstaert F et al. Trastuzumab in early stage breast cancer: A cost-effectiveness analysis for Belgium. Health Policy 2008; 87:146-159.
23. Garrison LP Jr, Lubeck D, Lalla D et al. Costeffectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. Cancer 2007;110:489-498.
24. Millar JA, Millward MJ. Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: A lifetime model. Pharmacoeconomics 2007;25:429-442.
25. Hall PS, Hulme C, McCabe C et al. Updated cost-effectiveness analysis of trastuzumab for early breast cancer: A UK perspective considering duration of benefit, long-term toxicity and pattern of recurrence. Pharmacoeconomics 2011;29:415-432.
26. Qaseem A, Alguire P, Dallas P et al. Appropriate use of screening and diagnostic tests to foster high-value, cost-conscious care. Ann Intern Med 2012;156:147-149.
27. Snyder L; American College of Physicians Ethics, Professionalism, and Human Rights Committee. American College of Physicians Ethics Manual: Sixth Edition. Ann Intern Med 2012;156: 73-104.
28. Laine C. High-value testing begins with a few simple questions. Ann Intern Med 2012;156: 162-163.